دورية أكاديمية
أعرض في EDS

Formulation, pharmacokinetics, and antibacterial activity of florfenicol-loaded niosome.

التفاصيل البيبلوغرافية
العنوان: Formulation, pharmacokinetics, and antibacterial activity of florfenicol-loaded niosome.
المؤلفون: Abonashey SG; Department of Biochemistry, Animal Health Research Institute, Dokki, Giza, Egypt., Hassan HAFM; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt. hatem.hassan@pharma.cu.edu.eg.; School of Life and Medical Sciences, University of Hertfordshire Hosted By Global Academic Foundation, New Administrative Capital, Cairo, Egypt. hatem.hassan@pharma.cu.edu.eg., Shalaby MA; Pharmacology Department, Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt., Fouad AG; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt., Mobarez E; Department of Biochemistry, Animal Health Research Institute, Dokki, Giza, Egypt., El-Banna HA; Pharmacology Department, Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt.
المصدر: Drug delivery and translational research [Drug Deliv Transl Res] 2024 Apr; Vol. 14 (4), pp. 1077-1092. Date of Electronic Publication: 2023 Nov 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 101540061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-3948 (Electronic) Linking ISSN: 2190393X NLM ISO Abbreviation: Drug Deliv Transl Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York : Springer
مواضيع طبية MeSH: Liposomes* , Escherichia coli*, Thiamphenicol/*analogs & derivatives, Animals ; Mice ; Staphylococcus aureus ; Chickens ; Anti-Bacterial Agents/pharmacology ; Body Weight
مستخلص: The growing interest in employing nano-sized pharmaceutical formulations in veterinary medicine has prompted the exploration of the novel nanocarriers' ability to augment the therapeutic outcome. In this study, we harnessed niosomes, spherical nanocarriers formed through non-ionic surfactant self-assembly, to enhance the therapeutic efficacy of the broad-spectrum antibiotic florfenicol. Pre-formulation studies were conducted to identify the optimal parameters for preparing florfenicol-loaded niosomes (FLNs). These studies revealed that the formulation that consisted of Span 60, cholesterol, and dihexadecyl phosphate (DDP) at a molar ratio of 1:1:0.1 exhibited the highest entrapment efficiency (%EE) and uniform size distribution. In vitro antibacterial testing demonstrated the niosomal capacity to significantly reduce florfenicol minimum inhibitory concentration (MIC) against E. coli and S. aureus. Pharmacokinetic profiles of free florfenicol and FLN were assessed following oral administration of 30 mg florfenicol/kg body weight to healthy or E. coli-infected chickens. FLN exhibited a substantially higher maximum plasma concentration (C max ) of florfenicol compared to free florfenicol. Furthermore, FLN showed significantly higher area under the curve (AUC 0-t ) than free florfenicol as revealed from the relative bioavailability studies. Lethal dose (LD) 50 values for both free florfenicol and FLN exceeded 5 g/kg of body weight, indicating high safety profile. Assessment of mortality protection in mice against lethal E. coli infections showed the significantly higher capability of FLN to improve the survival rate (75%) than free florfenicol (25%). Collectively, these findings demonstrate the niosomal ability to improve the oral bioavailability as well as the antibacterial activity of the incorporated veterinary antibiotic florfenicol.
(© 2023. The Author(s).)
References: J Vet Pharmacol Ther. 2016 Feb;39(1):84-9. (PMID: 25891823)
AAPS PharmSciTech. 2008;9(3):740-7. (PMID: 18563578)
Iran J Pharm Res. 2018;17(Suppl2):1-11. (PMID: 31011337)
Can Vet J. 1997 Sep;38(9):555-60. (PMID: 9285135)
J Control Release. 2021 Apr 10;332:419-433. (PMID: 33677010)
Drug Deliv Transl Res. 2018 Jun;8(3):633-644. (PMID: 29488171)
Arch Toxicol. 1981 Apr;47(2):77-99. (PMID: 7271444)
Vet J. 2015 Jul;205(1):21-7. (PMID: 25981931)
J Pharm Sci. 2022 May;111(5):1497-1508. (PMID: 34929155)
Pharmazie. 2021 Feb 25;76(2):77-83. (PMID: 33714283)
Drug Deliv. 2016 Nov;23(9):3653-3664. (PMID: 27886514)
ISRN Vet Sci. 2013 Oct 10;2013:167521. (PMID: 24222862)
Acta Pharm Sin B. 2017 May;7(3):260-280. (PMID: 28540164)
Br Poult Sci. 1997 Sep;38(4):425-8. (PMID: 9347153)
Pharmaceutics. 2021 Sep 26;13(10):. (PMID: 34683853)
Eur J Pharm Biopharm. 2016 May;102:101-14. (PMID: 26925505)
Vet Res Commun. 1993;17(4):295-303. (PMID: 8146955)
Sci Rep. 2017 Jan 30;7:41503. (PMID: 28134262)
J Colloid Interface Sci. 2007 Oct 1;314(1):230-5. (PMID: 17612555)
J Vet Pharmacol Ther. 1987 Sep;10(3):233-40. (PMID: 3656510)
J Sci Food Agric. 2014 Jan 30;94(2):301-7. (PMID: 23749768)
Can Vet J. 1999 Mar;40(3):179-84. (PMID: 10086218)
J Am Vet Med Assoc. 1980 May 15;176(10 Spec No):1085-90. (PMID: 7216877)
Acta Pharmacol Toxicol (Copenh). 1977 Nov;41(5):507-14. (PMID: 579561)
J Mater Chem B. 2013 Jun 7;1(21):2710-2718. (PMID: 32260976)
Pharmaceuticals (Basel). 2022 Oct 22;15(11):. (PMID: 36355478)
AAPS PharmSciTech. 2020 May 24;21(5):156. (PMID: 32449087)
J Adv Pharm Technol Res. 2010 Oct;1(4):374-80. (PMID: 22247876)
Antimicrob Agents Chemother. 1981 Feb;19(2):294-7. (PMID: 6957162)
Crit Care Med. 2008 Aug;36(8):2433-40. (PMID: 18596628)
J Appl Toxicol. 2009 Jan;29(1):69-78. (PMID: 18756589)
J Antimicrob Chemother. 1990 Sep;26(3):307-17. (PMID: 2228823)
J Vet Pharmacol Ther. 2018 Aug;41(4):588-598. (PMID: 29604071)
Methods Mol Biol. 2023;2622:57-63. (PMID: 36781749)
Pharm Dev Technol. 2013 May-Jun;18(3):667-72. (PMID: 22468904)
J Invest Dermatol. 2007 Jan;127(1):154-62. (PMID: 16858422)
J Vet Pharmacol Ther. 2007 Apr;30(2):145-50. (PMID: 17348900)
Vet Res Commun. 2007 Aug;31 Suppl 1:139-44. (PMID: 17682861)
IET Nanobiotechnol. 2015 Dec;9(6):355-61. (PMID: 26647811)
Antimicrob Agents Chemother. 2007 Nov;51(11):3781-8. (PMID: 17724157)
J Vet Pharmacol Ther. 2003 Oct;26(5):337-41. (PMID: 14633185)
Int J Pharm. 2013 Nov 18;456(2):446-58. (PMID: 23998955)
J Clin Microbiol. 1993 Sep;31(9):2332-8. (PMID: 8408551)
J Pharm Sci. 2018 May;107(5):1237-1246. (PMID: 29336980)
Front Microbiol. 2016 Mar 30;7:389. (PMID: 27065961)
Br Poult Sci. 1991 Jul;32(3):589-96. (PMID: 1893268)
Eur J Pharm Biopharm. 2007 May;66(2):227-43. (PMID: 17127045)
Br Poult Sci. 1998 Sep;39(4):492-6. (PMID: 9800032)
Res Vet Sci. 2002 Oct;73(2):137-40. (PMID: 12204631)
J Pharm Sci. 2019 Apr;108(4):1521-1528. (PMID: 30472265)
J Vet Pharmacol Ther. 1995 Dec;18(6):413-7. (PMID: 8789692)
AAPS PharmSciTech. 2018 May;19(4):1529-1543. (PMID: 29470829)
J Agric Food Chem. 2008 Nov 26;56(22):11049-56. (PMID: 18975969)
Int J Pharm. 2023 Mar 25;635:122776. (PMID: 36841370)
J Antibiot (Tokyo). 2011 Sep;64(9):625-34. (PMID: 21811264)
BMC Vet Res. 2023 Jun 30;19(1):81. (PMID: 37391757)
Am J Vet Res. 1987 Dec;48(12):1725-32. (PMID: 3434919)
Antimicrob Agents Chemother. 1980 Aug;18(2):311-6. (PMID: 7447408)
فهرسة مساهمة: Keywords: Antibacterial activity; Antibiotics; Florfenicol; Nanoparticles; Niosome; Oral delivery
المشرفين على المادة: 0 (Liposomes)
9J97307Y1H (florfenicol)
0 (Anti-Bacterial Agents)
FLQ7571NPM (Thiamphenicol)
تواريخ الأحداث: Date Created: 20231113 Date Completed: 20240312 Latest Revision: 20240314
رمز التحديث: 20240314
مُعرف محوري في PubMed: PMC10927884
DOI: 10.1007/s13346-023-01459-9
PMID: 37957473
قاعدة البيانات: MEDLINE
الوصف
تدمد:2190-3948
DOI:10.1007/s13346-023-01459-9